Jefferies London 2026: Protagonist Therapeutics' CEO Dinesh Patel discusses the launch of ICOTYDE, and the company's pipeline, which is well funded now due to commercial success

0:00-11:22

He comments on the early days of JNJ's ICOTYDE launch, developing an optimized IL-17, the obesity space, and more.

B-

BiotechTV - News

@biotechtvnews

#protagonisttherapeuticsceo #fundednowdue #commercialsuccess #lifesciences

The Nile